Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 11:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: everolimus-eluting stent Clear all
Completed No phase listed Observational Results available

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)

NCT00676520
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
XIENCE V® Everolimus Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
8,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Sep 21, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)

NCT01665053
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Plus, SYNERGY
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
69
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 21, 2026, 11:12 PM EDT
Completed Not applicable Interventional Results available

EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions

NCT01435031
View directory record Official record
Conditions
Coronary Artery Disease (CAD), Chronic Total Occlusion (CTO)
Interventions
CTO Treatment Device
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Sep 21, 2026, 11:12 PM EDT
Completed Phase 4 Interventional Results available

PROMUS Element Plus US Post-Approval Study

NCT01589978
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Plus Coronary Stent System, Aspirin, P2Y12 antagonist
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
2,681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
52
States / cities
Huntsville, Alabama • Mobile, Alabama • Jonesboro, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 21, 2026, 11:12 PM EDT
Completed Not applicable Interventional Results available

A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)

NCT01923740
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
XIENCE V EECSS, Absorb BVS System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 21, 2026, 11:12 PM EDT
Completed Not applicable Interventional Results available

Absorb IV Randomized Controlled Trial

NCT02173379
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Absorb BVS, XIENCE
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
98
States / cities
Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Sep 21, 2026, 11:12 PM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

NCT02389946
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia, Ischemic Heart Disease, Acute Coronary Syndrome, Angina Pectoris
Interventions
Orsiro DES, Xience DES
Device
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
55
States / cities
Fairhope, Alabama • Concord, California • La Mesa, California + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Sep 21, 2026, 11:12 PM EDT
Terminated Not applicable Interventional

Serial Evaluation of Drug-Eluting Stents Using OCT (STRUT-OCT)

NCT01962740
View directory record Official record
Conditions
Drug Eluting Stents (DES), Percutaneous Coronary Intervention (PCI), Uncovered and Malapposed Stent Struts, Optical Coherence Tomography (OCT)
Interventions
Drug-eluting stent implantation
Device
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
18 Years to 89 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Sep 21, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions

NCT00823212
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Coronary Stent System, PROMUS Element Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
75
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 21, 2026, 11:12 PM EDT
Completed Not applicable Interventional Results available

PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease

NCT03168776
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
BuMA Supreme DES, Xience or Promus DES
Device
Lead sponsor
Sino Medical Sciences Technology Inc.
Industry
Eligibility
20 Years and older
Enrollment
1,629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
40
States / cities
Birmingham, Alabama • Gilbert, Arizona • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 21, 2026, 11:12 PM EDT
Completed Not applicable Interventional Results available

HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt

NCT02073565
View directory record Official record
Conditions
Coronary Arteriosclerosis, Non ST Segment Elevation Acute Coronary Syndrome
Interventions
OrbusNeich Combo stent™, Everolimus Eluting Stent (EES)
Device
Lead sponsor
OrbusNeich
Industry
Eligibility
20 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
17
States / cities
Washington D.C., District of Columbia • Lake Worth, Florida • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Sep 21, 2026, 11:12 PM EDT
Completed No phase listed Observational

Registry Experience at the Washington Hospital Center, DES - Xience V

NCT01003977
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Rebecca Torguson
Other
Eligibility
18 Years and older
Enrollment
6,069 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 1, 2020 · Synced Sep 21, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s)

NCT03350542
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
SYNERGY 48 mm
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Birmingham, Alabama • Saint Paul, Minnesota • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Sep 21, 2026, 11:12 PM EDT
Recruiting Not applicable Interventional

MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels

NCT06271590
View directory record Official record
Conditions
Coronary Artery Disease, Native Coronary Artery Stenosis, Cardiovascular Diseases
Interventions
Sirolimus Drug Coated Balloon, Drug eluting stents (DES)
Device
Lead sponsor
Concept Medical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
24
States / cities
Gilbert, Arizona • Los Angeles, California • Clearwater, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 21, 2026, 11:12 PM EDT
Terminated Not applicable Interventional Results available

SPIRIT Small Vessel Registry

NCT00783796
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Myocardial Ischemia
Interventions
2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
34
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Washington D.C., District of Columbia + 29 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 21, 2026, 11:12 PM EDT
Completed No phase listed Observational

XIENCE V® EXCEED: Evaluation of XIENCE V® Catheterization Lab Endpoints and Excellence in Delivery

NCT00731237
View directory record Official record
Conditions
Atherosclerosis, Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
2,517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
44
States / cities
Huntsville, Alabama • Mesa, Arizona • Hot Springs, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Sep 21, 2026, 11:12 PM EDT
Completed No phase listed Observational

Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents

NCT00638794
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Drug -Eluting Stent (Taxus™, Cypher®, Endeavor™, Xience V™)
Device
Lead sponsor
Cardiovascular Research Foundation, New York
Other
Eligibility
18 Years and older
Enrollment
8,575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
8
States / cities
Minneapolis, Minnesota • New York, New York • Charlotte, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 21, 2026, 11:12 PM EDT
Completed Not applicable Interventional Results available

Wall Shear Stress and Neointimal Healing Following PCI in Angulated Coronary Vessels

NCT02098876
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Resolute Integrity Zotarolimus eluting stent, Xience Xpedition everolimus eluting stent, Optical Coherence Tomography (OCT), Intravascular Ultrasound (IVUS)
Device
Lead sponsor
Emory University
Other
Eligibility
30 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Sep 21, 2026, 11:12 PM EDT
Completed Phase 4 Interventional Results available

XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort

NCT01106534
View directory record Official record
Conditions
Chronic Total Occlusion of Coronary Artery, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
placebo + aspirin, clopidogrel + aspirin OR prasugrel + aspirin, XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
Drug · Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
144
States / cities
Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Sep 21, 2026, 11:12 PM EDT
Completed Phase 3 Interventional

Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry

NCT03048825
View directory record Official record
Conditions
ST Elevation Myocardial Infarction, Non ST Elevation Myocardial Infarction
Interventions
Colchicine, Spironolactone, SYNERGY Bioabsorbable Polymer Drug-Eluting Stent, Colchicine-Placebo, Spironolactone-Placebo
Drug · Device
Lead sponsor
Population Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
7,264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
11
States / cities
Bakersfield, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 21, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System

NCT00307047
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
XIENCE V® Everolimus Eluting Coronary Stent, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
3,687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
65
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Fairfax, California + 54 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Sep 21, 2026, 11:12 PM EDT
Completed No phase listed Observational Results available

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study

NCT01249027
View directory record Official record
Conditions
Angioplasty, Chronic Coronary Occlusion, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
2,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Sep 21, 2026, 11:12 PM EDT
Completed Not applicable Interventional Results available

ABSORB III Randomized Controlled Trial (RCT)

NCT01751906
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Absorb BVS, XIENCE
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,008 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
190
States / cities
Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 145 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 21, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

NCT00180479
View directory record Official record
Conditions
Stents, Coronary Artery Disease, Total Coronary Occlusion, Coronary Artery Restenosis, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
Interventions
XIENCE V® Everolimus Eluting Coronary Stent, TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 56 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Sep 21, 2026, 11:12 PM EDT